NO985645L - Membran-inkorporering av texafyriner - Google Patents
Membran-inkorporering av texafyrinerInfo
- Publication number
- NO985645L NO985645L NO985645A NO985645A NO985645L NO 985645 L NO985645 L NO 985645L NO 985645 A NO985645 A NO 985645A NO 985645 A NO985645 A NO 985645A NO 985645 L NO985645 L NO 985645L
- Authority
- NO
- Norway
- Prior art keywords
- texaphyrin
- molecule conjugate
- lipophilic molecule
- loaded
- cells loaded
- Prior art date
Links
- 238000010348 incorporation Methods 0.000 title 1
- 239000012528 membrane Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000003743 erythrocyte Anatomy 0.000 abstract 2
- 239000002502 liposome Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000002583 angiography Methods 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002872 contrast media Substances 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 230000005291 magnetic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000005298 paramagnetic effect Effects 0.000 abstract 1
- 238000002428 photodynamic therapy Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T15/00—3D [Three Dimensional] image rendering
- G06T15/10—Geometric effects
- G06T15/20—Perspective computation
- G06T15/205—Image-based rendering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Hematology (AREA)
- Radiology & Medical Imaging (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Computer Graphics (AREA)
- Computing Systems (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Geometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65794796A | 1996-06-04 | 1996-06-04 | |
| PCT/US1997/009501 WO1997046262A2 (en) | 1996-06-04 | 1997-06-04 | Membrane incorporation of texaphyrins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO985645D0 NO985645D0 (no) | 1998-12-03 |
| NO985645L true NO985645L (no) | 1999-02-03 |
Family
ID=24639282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO985645A NO985645L (no) | 1996-06-04 | 1998-12-03 | Membran-inkorporering av texafyriner |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0954336B1 (no) |
| JP (1) | JP2000512279A (no) |
| CN (1) | CN1225591A (no) |
| AT (1) | ATE260121T1 (no) |
| AU (1) | AU727138B2 (no) |
| BR (1) | BR9710685A (no) |
| CA (1) | CA2257225A1 (no) |
| DE (1) | DE69727833T2 (no) |
| IL (1) | IL127315A (no) |
| NO (1) | NO985645L (no) |
| NZ (1) | NZ333072A (no) |
| WO (1) | WO1997046262A2 (no) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888997A (en) * | 1994-04-14 | 1999-03-30 | Pharmacyclics, Inc. | Radiation sensitization using texaphyrins |
| US6375930B2 (en) | 1996-06-04 | 2002-04-23 | Board Of Regents, The University Of Texas System | Membrane incorporation of texaphyrins |
| BR9714642A (pt) * | 1996-12-11 | 2000-10-03 | Pharmacyclics Inc | "uso de texafirina na preparação de um medicamento para uso em diagnóstico e terapia ocular" |
| US6270749B1 (en) | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
| US6183727B1 (en) * | 1998-05-19 | 2001-02-06 | Arizona Board Of Regents | Use of long-wavelength electromagnetic radiation and photoprotective tumor localizing agents for diagnosis |
| WO2000041726A2 (en) * | 1999-01-15 | 2000-07-20 | Light Sciences Corporation | Noninvasive vascular therapy |
| EP1206288B1 (en) * | 1999-08-02 | 2007-01-10 | The Regents Of The University Of Michigan | Targeted fiberless radiative effectors |
| US6944493B2 (en) | 1999-09-10 | 2005-09-13 | Akora, Inc. | Indocyanine green (ICG) compositions and related methods of use |
| AU7106400A (en) * | 1999-09-10 | 2001-04-10 | Akorn, Inc. | Fluorescent dye angiography and dye-enhanced photocoagulation |
| US6351663B1 (en) | 1999-09-10 | 2002-02-26 | Akorn, Inc. | Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation |
| US6443976B1 (en) | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
| US6319273B1 (en) * | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
| US7112671B2 (en) | 2000-08-30 | 2006-09-26 | Pharmacyclics, Inc. | Non-symmetric tripyrranes in the synthesis of novel macrocycles |
| US6638924B2 (en) | 2000-08-30 | 2003-10-28 | Pharmacyclics, Inc. | Metallotexaphyrin derivatives |
| US7449454B2 (en) | 2000-08-30 | 2008-11-11 | Pharmacyclics, Inc. | Metallotexaphyrin derivatives |
| EP1684723A4 (en) * | 2003-11-21 | 2007-06-20 | Fujifilm Corp | CONTRAST MEDIUM COMPRISING LIPOSOMES CONTAINING A HYDROPHOBIC CHELATE COMPOUND |
| US20070072838A1 (en) | 2005-09-26 | 2007-03-29 | Pharmacyclics, Inc. | High-purity texaphyrin metal complexes |
| WO2016165006A1 (en) * | 2015-04-17 | 2016-10-20 | University Health Network | Texaphyrin-phospholipid conjugates and methods of preparing same |
| CN111265674A (zh) * | 2020-03-24 | 2020-06-12 | 浙江大学医学院附属第四医院(浙江省义乌医院、浙江大学医学院附属第四医院医共体) | 一种造影剂、造影剂的制备方法及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457183A (en) * | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5599923A (en) * | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
| US5120411A (en) * | 1989-12-21 | 1992-06-09 | Board Of Regents, The University Of Texas System | Photodynamic activity of sapphyrins |
| US5591422A (en) * | 1995-06-02 | 1997-01-07 | Pharmacyclics, Inc. | Texaphyrin complexes having improved functionalization |
-
1997
- 1997-06-04 AT AT97927923T patent/ATE260121T1/de not_active IP Right Cessation
- 1997-06-04 AU AU32264/97A patent/AU727138B2/en not_active Ceased
- 1997-06-04 NZ NZ333072A patent/NZ333072A/en unknown
- 1997-06-04 CA CA002257225A patent/CA2257225A1/en not_active Abandoned
- 1997-06-04 DE DE1997627833 patent/DE69727833T2/de not_active Expired - Fee Related
- 1997-06-04 JP JP10500764A patent/JP2000512279A/ja active Pending
- 1997-06-04 CN CN97196446A patent/CN1225591A/zh active Pending
- 1997-06-04 IL IL12731597A patent/IL127315A/xx not_active IP Right Cessation
- 1997-06-04 BR BR9710685-2A patent/BR9710685A/pt not_active IP Right Cessation
- 1997-06-04 EP EP97927923A patent/EP0954336B1/en not_active Expired - Lifetime
- 1997-06-04 WO PCT/US1997/009501 patent/WO1997046262A2/en active IP Right Grant
-
1998
- 1998-12-03 NO NO985645A patent/NO985645L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997046262A3 (en) | 1998-03-12 |
| IL127315A (en) | 2003-05-29 |
| IL127315A0 (en) | 1999-09-22 |
| AU3226497A (en) | 1998-01-05 |
| JP2000512279A (ja) | 2000-09-19 |
| CN1225591A (zh) | 1999-08-11 |
| DE69727833T2 (de) | 2005-01-13 |
| NZ333072A (en) | 2000-06-23 |
| AU727138B2 (en) | 2000-12-07 |
| BR9710685A (pt) | 2000-01-11 |
| EP0954336B1 (en) | 2004-02-25 |
| CA2257225A1 (en) | 1997-12-11 |
| NO985645D0 (no) | 1998-12-03 |
| EP0954336A2 (en) | 1999-11-10 |
| ATE260121T1 (de) | 2004-03-15 |
| DE69727833D1 (de) | 2004-04-01 |
| WO1997046262A2 (en) | 1997-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO985645L (no) | Membran-inkorporering av texafyriner | |
| CA1324051C (en) | Ultrasound enhancement of transdermal drug delivery | |
| ATE99544T1 (de) | Liposomale radiologische kontrastmittel. | |
| Jackson et al. | High dose intravenous vitamin C and long time survival of a patient with cancer of the head of the pancreas | |
| Place et al. | MRI contrast-dose relationship of manganese (III) tetra (4-sulfonatophenyl) porphyrin with human xenograft tumors in nude mice at 2.0 T | |
| JPH05501856A (ja) | 脳及び筋肉組織傷害による浮腫の治療剤 | |
| Stewart et al. | The treatment of patients with interstitial cystitis, with special reference to intravesical DMSO | |
| Ley et al. | Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: neurobehavior, histopathology, and pharmacokinetics | |
| Espert et al. | Evaluation of risk of splenosis during laparoscopic splenectomy in rat model | |
| CA2269364A1 (en) | Treatment of inflammatory and allergic disorders | |
| WO2007122280A1 (es) | Uso del factor de crecimiento de hígado (lgf) como regenerador tisular pleiotrópico | |
| RU2228145C2 (ru) | Способ профилактики инфекционно-воспалительных и тромбогеморрагических осложнений у больных, оперированных по поводу доброкачественной гиперплазии предстательной железы | |
| RU2161036C2 (ru) | Способ лечения хронических диффузных заболеваний печени | |
| Zima et al. | The localisation of TPPS~ 4 in some organs and its possible nephrotoxicity in rats | |
| RU2144364C1 (ru) | Способ лечения больных с лимфедемой конечностей | |
| SU1717105A1 (ru) | Способ рентгенологического исследовани желчевывод щих путей | |
| RU2088277C1 (ru) | Способ селективного транспорта и депонирования лекарственных веществ в стоматологии | |
| Moreau et al. | Haemodynamic effects of octreotide in portal hypertensive rats receiving propranolol | |
| DE19654186A1 (de) | Verbindungen zur Behandlung von Tumoren und deren Verwendung zur Herstellung von Arzneimitteln | |
| Abdollahi et al. | New approach to the efficacy of oximes in the management of acute organophosphates poisoning | |
| Nuernberg et al. | Anti-inflammatory effects and disposition of S-and R-flurbiprofen in the rat | |
| Piller et al. | The effect of coumarin (5, 6 benzo-α-pyrone) on elicited members of the mononuclear system in dogs with chronic secondary lymphedema | |
| UA29799A (uk) | Спосіб профілактики та лікування післяопераційного панкреатиту | |
| Batstone et al. | Uretric obstruction in Gardener's syndrome | |
| Ushiyama et al. | Physiological Effects of Continuous Whole-Body Exposure to Extremely Low Frequency Electromagnetic Fields With or Without Transient Magnetic Fields on Cerebral Microcirculation in Mice With Brain Tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |